Table 1.
Treatment summary for all genotypes
| Recommended | Genotype 1 | |||
|---|---|---|---|---|
| Treatment | Duration | SVR | Study | |
| SOF/LDV FDC | 8–24 WEEKS | 94–99% | ION I, II, III[38, 39, 47] | |
| SOF/SIM | 12–24 WEEKS | 92% | COSMOS[27] | |
| Alternative Therapy IFN eligible | SMV +RBV/PegIFN | 24WEEKS | 93% | QUEST[61] |
| SOF + RBV/PegIFN | 12 WEEKS | 89% (80% in cirrhotics) | NEUTRINO[49, 56] | |
| Genotype 2 | ||||
| Recommended | SOF +RBV | 12–16 WEEKS | 94% | FISSION, POSITRON & VALENCE[44, 52] |
| Genotype 3 | ||||
| Recommended Rx naive) | SOF +RBV | 24 WEEKS | 93% | VALENCE[44] |
| Alternative | SOF +RBV +PegIFN | 12 WEKS | 97% | PROTON & ELECTRON[53, 54] |
| Genotype 4 | ||||
| Recommended | SOF + RBV + PegIFN | 12 WEEKS | NEUTRINO[56] | |
| SOF +RBV | 24 WEEKS | |||
| SOF/LDV FDC | 12 WEEKS | 95% | SYNERGY[59] | |
| Paritepravir/ritonavir, ombitasvir, dasabuvir ± RBV | 12 WEEKS | 91%-100% | PEARL-1[58] | |
| Genotype 5/6 | ||||
| Recommended | SOF +RBV + PegIFN | 12 WEEKS | NEUTRINO[56] | |
| (GT6) | SOF/LDV FDC | 12 WEEKS | 96% | AASLD[60] |
Abbreviations: SOF=Sofosbuvir (400mg/daily); SMV= Simeprevir (150mg/daily); PegIFN= Pegylated interferon (180μg/weekly sc); RBV= Ribavirin (weight based 1000mg <75kg and 1200 >75kg; LDV= Ledipasvir (90mg);